DC-CIK细胞联合常规治疗对肾透明细胞癌患者的临床疗效

发布时间：2019-04-11 15:00

【摘要】：目的:探讨DC-CIK细胞治疗肾透明细胞癌临床疗效及治疗次数对患者预后的影响。方法:回顾性分析2004年1月至2011年6月在福建省肿瘤医院诊疗的100例肾透明细胞癌患者,其中63例在福建省肿瘤生物治疗重点实验室进行自体DC-CIK细胞免疫治疗联合常规治疗为DC-CIK细胞治疗组,其余37例未经DC-CIK细胞治疗为对照组,比较两组患者的5年DFS和OS。治疗组按照DC-CIK细胞治疗疗程数分成≤3个疗程组及3个疗程组,分析DC-CIK细胞治疗疗程数对肾透明细胞癌患者5年DFS和OS的相关性。结果:DC-CIK细胞治疗组患者5年OS较对照组明显提高(81.05%vs 60.29%,P0.05),但5年DFS无显著性差异(P0.05);DC-CIK细胞治疗疗程数3个的患者5年OS较对照组明显提高(P0.05),但5年DFS无显著性差异(P0.05)。结论:自体DC-CIK细胞回输联合常规治疗手段治疗肾透明细胞癌更有生存优势,且DC-CIK细胞治疗疗程数与肾透明细胞癌患者的预后密切相关。
[Abstract]:Objective: to investigate the clinical efficacy of DC-CIK cells in the treatment of renal clear cell carcinoma (RCC) and the effect of the times of treatment on the prognosis of the patients. Methods: 100 patients with renal clear cell carcinoma diagnosed and treated in Fujian Cancer Hospital from January 2004 to June 2011 were retrospectively analyzed. Among them, 63 cases were treated with autologous DC-CIK cell immunotherapy combined with routine therapy in Fujian Provincial key Laboratory of Cancer Biotherapy, and the other 37 cases were treated without DC-CIK cells as control group. Comparison of 5-year DFS and OS. between the two groups The patients in the treatment group were divided into 鈮，

本文编号：2456506